{"filing":{"accession_number":"0001171843-26-005406","cik":"0001123494","ticker":"HBIO","company_name":"HARVARD BIOSCIENCE INC","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"f8k_081126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326005406/f8k_081126.htm"},"events":[{"id":26841,"run_id":24412,"accession_number":"0001171843-26-005406","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This Item 7.01 disclosure furnishes a corporate investor presentation that updates the investment community on Harvard Bioscience's business strategy, recent actions, and financial guidance. The presentation covers multiple material operational and strategic developments including new executive leadership (CEO and CFO appointments), debt refinancing with extended maturity and $3M annual cash savings, board expansion, manufacturing consolidation (Project Viking) expected to deliver $3-4M EBITDA improvement, and a strategic refocus on Translational Science products. While these individual items might fit specific categories (exec_appointment, debt_issuance, workforce_reduction), the disclosure as a whole is a comprehensive investor update that does not center on any single event type but rather presents an integrated strategic narrative. The operational and strategic nature of the content, combined with the lack of a single dominant event, makes operational_other the most appropriate classification.","company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28115,"accession_number":"0001171843-26-005406","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 7.01 disclosure furnishes a corporate investor presentation that updates the investment community on Harvard Bioscience's business strategy, recent actions, and financial guidance. The presentation covers multiple material operational and strategic developments including new executive leadership (CEO and CFO appointments), debt refinancing with extended maturity and $3M annual cash savings, board expansion, manufacturing consolidation (Project Viking) expected to deliver $3-4M EBITDA improvement, and a strategic refocus on Translational Science products. While these individual items might fit specific categories (exec_appointment, debt_issuance, workforce_reduction), the disclosure as a whole is a comprehensive investor update that does not center on any single event type but rather presents an integrated strategic narrative. The operational and strategic nature of the content, combined with the lack of a single dominant event, makes operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:04:00.958213+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28115,"accession_number":"0001171843-26-005406","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This Item 7.01 disclosure furnishes a corporate investor presentation that updates the investment community on Harvard Bioscience's business strategy, recent actions, and financial guidance. The presentation covers multiple material operational and strategic developments including new executive leadership (CEO and CFO appointments), debt refinancing with extended maturity and $3M annual cash savings, board expansion, manufacturing consolidation (Project Viking) expected to deliver $3-4M EBITDA improvement, and a strategic refocus on Translational Science products. While these individual items might fit specific categories (exec_appointment, debt_issuance, workforce_reduction), the disclosure as a whole is a comprehensive investor update that does not center on any single event type but rather presents an integrated strategic narrative. The operational and strategic nature of the content, combined with the lack of a single dominant event, makes operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:04:00.958213+00:00","company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","filing_date":"2026-08-11"}]}